AIM
PETX

Acrospire Investment Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Acrospire Investment Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,861
Closed -$20K – 2735
2017
Q1 		$20K Sell
3,861
-9,600
-71% -$64.8K 0.02% 1642
2016
Q4 		$97K Sell
13,461
-1,105
-8% -$8.94K 0.04% 952
2016
Q3 		$136K Buy
+14,566
New +$121K 0.09% 325

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Acrospire Investment Management's PETX Position: Q2 2017 in Review

Acrospire Investment Management sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2017, closing a stake of 3,861 shares — an estimated $20K sold.

Acrospire Investment Management first reported a position in PETX in Q3 2016 and held it in 3 quarters. The position peaked at $136K in Q3 2016. 105 funds tracked by Wall St. Rank hold PETX as of Q2 2017.

  • Acrospire Investment Management reported no remaining Aratana Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 3,861 Aratana Therapeutics, Inc. shares in Q2 2017, an estimated $20K.
  • Acrospire Investment Management first reported a position in Aratana Therapeutics, Inc. in Q3 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Aratana Therapeutics, Inc. position peaked at $136K in Q3 2016.
  • 105 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.